259 related articles for article (PubMed ID: 9661818)
1. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
[TBL] [Abstract][Full Text] [Related]
2. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
[TBL] [Abstract][Full Text] [Related]
3. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
Perlman DC; Gourevitch MN; Trinh C; Salomon N; Horn L; Des Jarlais DC
J Urban Health; 2001 Sep; 78(3):550-67. PubMed ID: 11564856
[TBL] [Abstract][Full Text] [Related]
5. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Hitimana-Lukanika C; Odeke R; Madra P; Adatu F; Blandford JM
Int J Tuberc Lung Dis; 2006 Jun; 10(6):656-62. PubMed ID: 16776453
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools.
Yuan L; Richardson E; Kendall PR
CMAJ; 1995 Oct; 153(7):925-32. PubMed ID: 7553494
[TBL] [Abstract][Full Text] [Related]
8. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Sutton BS; Arias MS; Chheng P; Eang MT; Kimerling ME
Int J Tuberc Lung Dis; 2009 Jun; 13(6):713-8. PubMed ID: 19460246
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings].
Yoshiyama T
Kekkaku; 2000 Nov; 75(11):629-41. PubMed ID: 11140086
[TBL] [Abstract][Full Text] [Related]
10. Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia.
Heal G; Elwood RK; FitzGerald JM
Int J Tuberc Lung Dis; 1998 Dec; 2(12):979-83. PubMed ID: 9869112
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
Snyder DC; Paz EA; Mohle-Boetani JC; Fallstad R; Black RL; Chin DP
Am J Respir Crit Care Med; 1999 Jul; 160(1):178-85. PubMed ID: 10390397
[TBL] [Abstract][Full Text] [Related]
12. Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa.
Nuwaha F
East Afr Med J; 1998 Sep; 75(9):520-7. PubMed ID: 10493054
[TBL] [Abstract][Full Text] [Related]
13. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
[TBL] [Abstract][Full Text] [Related]
15. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine.
Nettleman MD; Geerdes H; Roy MC
Arch Intern Med; 1997 May; 157(10):1121-7. PubMed ID: 9164378
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Sterling TR; Brehm WT; Moore RD; Chaisson RE
Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alternative strategies for tuberculosis screening before kindergarten entry.
Flaherman VJ; Porco TC; Marseille E; Royce SE
Pediatrics; 2007 Jul; 120(1):90-9. PubMed ID: 17606566
[TBL] [Abstract][Full Text] [Related]
19. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
Foster S; Godfrey-Faussett P; Porter J
AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
